Identifying potentially disruptive biopharmaceutical companies within a sea of less compelling opportunities

The Rapha Capital Mission is to use our unique abilities to identify at the earliest stage, those companies that we believe will go on to profoundly improve peoples’ lives while building great value, from a sea of seemingly indistinguishable, less compelling, opportunities.

Rapha Capital Management is focused on identifying and growing revolutionary ideas in medicine, healthcare and technology before others can see their value.

Rapha Capital Management, LLC, founded in mid-2018, has grown to include 13 managed entities, Rapha Capital Investment I – XIII.

Poseida Therapeutics Logo

Poseida Therapeutics, Inc.

NexImmune Icon

NexImmune, Inc.

Rapha Capital Latest News

NEW POST

June 14, 2021 in Demeetra Agbio, Portfolio, Rapha Capital Management

CRISPR Medicine News Interview with Demeetra AgBio CEO, Jack Crawford

Demeetra Agbio, a Rapha portfolio company was recently featured in an article in the leading industry publication, CRISPR News MEDICINE.…
Read More

NEW POST

June 14, 2021 in K2 Biolabs, Ponce Therapeutics, Portfolio, Rapha Capital Management

New Biotechnology Research Accelerator Launches in Houston

K2-BioLabs offers “big company” resources that accommodate “small company” budgets Rapha Portfolio Company PONCE Therapeutics, Inc. is an investor and…
Read More
May 17, 2021 in Poseida Therapeutics, Inc., Rapha Capital Management

BTIG Research and Strategy: Cell Therapy is Coming – Our Picks Beyond the Wall

WHAT YOU SHOULD KNOW: We are initiating coverage on six companies that we believe are undervalued players in the cell…
Read More